BPIQ-II is a potent and selective inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase (IC50 = 8 pM), exhibiting superior selectivity for EGFR over other tyrosine and serine/threonine kinases; it effectively blocks EGF-stimulated signaling by competitively binding to the ATP-binding site of EGFR in cells.